Key Takeaways:
- Guidance Raised: Elevance Health lifted 2026 adjusted EPS guidance to at least $27, up from prior levels, after a strong Q2.
- Price Projection: Based on current execution, ELV stock could reach $494 by December 2028.
- Potential Gains: This target implies a total return of 19% from the current price of $417.
- Annual Return: Investors could see roughly 8% annualized growth over the next 2.3 years.
Now Live: Discover how much upside your favorite stocks could have using TIKR’s new Valuation Model (It’s free)>>>
Elevance Health (ELV) delivered Q2 results ahead of expectations, with adjusted diluted EPS of $7.45. The company raised full-year guidance to at least $27 per share and reaffirmed its plan to return to 12% adjusted EPS growth in 2027.
CEO Gail Boudreaux said the beat wasn’t tied to one business line. Medicare Advantage benefited from deliberate portfolio changes made for 2026, the individual ACA business tracked in line with plan, and Carelon, the company’s health services arm, continued to scale.
Medicaid remains the soft spot. The segment is expected to post a roughly negative 1.75% operating margin for the year, though management called 2026 the trough and expects gradual improvement as rates catch up with costs.
Elevance also agreed to exit the Washington, D.C., Medicaid market and expects to leave more state markets over the next 12 to 18 months where the economics don’t work.
ELV trades around $417 today, and investors are weighing this Medicaid uncertainty against improving performance everywhere else.
See analysts’ full growth forecasts and estimates for ELV stock (It’s free) >>>
What the Model Says for Elevance Health Stock
Elevance is one of the largest health insurers in the country, running Medicaid, Medicare Advantage, commercial, and individual ACA plans, plus Carelon, its fast-growing services and pharmacy business.
Medicare Advantage is on track for at least a 2% operating margin this year, helped by more focused plan design and better-than-expected claims experience.
Management priced its 2027 bids with similar discipline, aiming to keep that momentum going rather than chasing growth at the expense of margins.
Carelon is becoming a bigger part of the story too. Its CareBridge program, which extends care coordination into patients’ homes, has generated medical savings in the mid-teens range for enrolled members, and management is expanding it into new markets.
Carelon’s behavioral health programs have delivered average cost savings of 10%.
On Medicaid specifically, management stressed the cost pressure is concentrated in identifiable areas, behavioral health, specialty pharmacy, and emergency room use, rather than a broad reset in how sick the member base is.
That distinction matters because it means the problem is more fixable through targeted action than a structural shift in who’s enrolled.
Using a forecast of 5.0% annual revenue growth and 4.8% operating margins, our model projects the stock could reach $494 within 2.3 years. This assumes a 12.7x price-to-earnings multiple, below ELV’s own one-year average of 13.1x.
Our Valuation Assumptions
Estimate a company’s fair value instantly (Free with TIKR) >>>
Our Valuation Assumptions
TIKR’s Valuation Model lets you plug in your own assumptions for a company’s revenue growth, operating margins, and P/E multiple, and calculates the stock’s expected returns.
Here’s what we used for Elevance Health stock:
1. Revenue Growth: 5.0%
Elevance Health grew revenue 12.6% over the past year, well above its five- and ten-year averages of roughly 10%.
Q2 revenue growth slowed as Medicaid and individual ACA membership declined.
We’re assuming growth settles near 5% as the company prioritizes margin discipline and market exits over raw membership growth.
2. Operating Margin Growth: 4.8%
For the full year 2025, operating margin stood at 4.2%, below the five- and ten-year averages of roughly 5-6%.
Medicaid’s negative margin is the main drag right now.
Management expects gradual improvement as rates realign with costs and care management actions mature, but we’re keeping margins conservative given the multi-year timeline involved.
3. Exit P/E Multiple: 12.7x
Elevance Health currently trades at 15.3x forward earnings, above its five-year average of 13.7x.
We’re assuming some compression back toward that five-year average, reflecting the ongoing uncertainty around Medicaid margins and regulatory changes like new federal work requirements that could add complexity even if management believes the impact will be manageable.
Build your own Valuation Model to value any stock (It’s free!) >>>
What Happens If Things Go Better or Worse?
Health insurers face real swings depending on medical cost trends and government reimbursement rates. Here’s how Elevance Health stock might perform under different scenarios through December 2030:
- Low Case: If revenue growth slows to 3.3% and net income margins settle at 3.1%, investors could still see a 6.1% total return, or about 1.4% annually.
- Mid Case: With 3.7% growth and 3.3% margins, we expect a total return of 27.9%, or roughly 5.9% annually.
- High Case: If Medicaid margins recover faster than expected and Medicare Advantage and Carelon keep outperforming, returns could reach 49.4% total, or about 9.8% annually, with revenue growth at 4.0% and margins at 3.4%.
See what analysts think about ELV stock right now (Free with TIKR) >>>
The spread between these outcomes largely depends on how quickly Medicaid rates catch up with rising costs, how many additional state markets Elevance ultimately exits, and whether new federal work requirements create meaningful disruption or prove as manageable as management currently expects.
How Much Upside Does Elevance Health Stock Have From Here?
With TIKR’s new Valuation Model tool, you can estimate a stock’s potential share price in under a minute.
All it takes is three simple inputs:
- Revenue Growth
- Operating Margins
- Exit P/E Multiple
If you’re not sure what to enter, TIKR automatically fills in each input using analysts’ consensus estimates, giving you a quick, reliable starting point.
From there, TIKR calculates the potential share price and total returns under Bull, Base, and Bear scenarios so you can quickly see whether a stock looks undervalued or overvalued.
See a stock’s true value in under 60 seconds (Free with TIKR) >>>
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
